• New Gut Peptide Discovery Opens Door to Allergy Treatment

    Dec 18 | Diagnostics World News | Researchers have identified a previously overlooked mechanism controlling allergic reactions in the gut, potentially paving the way for novel treatments for conditions ranging from food allergies to irritable bowel syndrome. More

  • AI Enabling Clinical-Grade, Wearable-Based Sleep Tracking

    Dec 16 | Diagnostics World News | Good sleep patterns impact many aspects of the broader health status of individuals, but the measurement of slumber quality tends to fall at the extremes of either simplistic sleep logs or cumbersome in-patient sleep studies, or polysomnography. A new sleep-staging framework driven by artificial intelligence and an associated Apple Watch app known as BIDSleep is designed to bridge that gap by turning a smartwatch into a sleep-staging device that can distinguish between light, deep, and rapid eye movement sleep. More

  • Illumina Invests, Partners with MyOme AI-integrated Risk Models

    Dec 11 | Diagnostics World News | Illumina today announced an investment and collaboration into MyOme, a genomics and risk modeling company. The collaboration and investment will help advance MyOme’s Proactive Health (MPH) Trial—a clinical trial seeking to quantify the cost savings and improved patient outcomes for whole-genome sequencing (WGS) combined with MyOme’s AI-integrated risk models (IRMs)—and help expand MyOme’s suite of proactive health and rare disease diagnostic tests. Neither financial details nor milestones of the investment were disclosed. More

  • Precision Diagnostics Emerging from Psychedelic Psychiatry

    Dec 10 | Diagnostics World News | Thanks to promising developments in psychedelic and dissociative compounds, treatments for depression are likely to significantly change in the next 10 years. However, psychedelics also come with their own set of complications and side effects, such as disconnection from oneself and one’s surroundings and cardiovascular changes. More

  • Oxford Nanopore Chooses New CEO With Diagnostics Expertise

    Dec 08 | Diagnostics World News | Oxford Nanopore Technologies named a new CEO this morning, choosing an executive with extensive diagnostics experience. Francis Van Parys, currently CEO of Radiometer, will join Oxford Nanopore and the Board as an Executive Director on March 2, 2026. More

  • How Diagnostics in the Final Frontier Will Affect Those Back Home

    Dec 04 | Diagnostics World | When SpaceX’s Inspiration4 lifted off in 2021, it launched new opportunities for commercial space travel and raised new questions about how a space environment impacts the human body. TrialX believes what we learn about biology in space will not only expand our understanding of extreme environments’ impact on human health but will deepen our understanding of how biomarkers and health data are best gathered and explored at home as well. More

  • Variant Effect Map of Heart Attack Gene Could Aid Early Disease Detection

    Dec 02 | Diagnostics World | Increasing use of genetic testing to identify people at risk for various diseases has led to a skyrocketing number of never-before-seen variants with uncertain connections to those health conditions, making them impractical to investigate one by one as they once were. Clever bench scientists therefore began making all possible variants in genes with a suspected link to a disease or a patient's symptoms about 15 years ago, to determine which ones are most likely pathogenic. More

  • Follow the Money: Baylor College’s Customized Models, Whole-Body Chronic Disease Monitoring, More

    Nov 25 | Diagnostics World | Baylor College of Medicine will continue to create customized cell, fly, and mouse models to study rare genetic diseases; Curve Biosciences will advance the clinical validation and commercialization of their Whole-Body Intelligence platform for chronic disease monitoring; and more. More

  • Philips Extends Partnership with Cortechs.ai, Rapid Diagnostic Sepsis Test, Nucleai, University of Glasgow Collaboration

    Nov 24 | Diagnostics World | Royal Philips extended their partnership with Cortechs.ai; OCEAN Dx completes a clinical evaluation study for its innovative rapid diagnostic test for sepsis; Nucleai and the University of Glasgow announce a collaboration; and more. More

  • Multiple Biological Dimensions In A Single Assay

    Nov 19 | Diagnostics World | Watchmaker Genomics has launched TAPS+, a next-generation technology that unites genetic and epigenetic readouts from the same DNA molecule. By capturing multiple biological dimensions in a single assay, TAPS+ delivers a richer, more comprehensive view of tumor biology, with the power to advance applications in translational oncology, early cancer detection, therapy response monitoring, fragmentomics, and minimal residual disease assessment. More
View more articles

 
DXX-Industry-spotlight

merck


Custom Diagnostic Antibody Development & Manufacturing Services

Overcome Process Challenges by outsourcing your custom antibody production to us. How partnering with an antibody production expert can improve your assay, accelerate launch, and maintain your manufacturing.

Learn more